Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates
Positive IHL-42X PK findings for the treatment of Obstructive Sleep Apnea (OSA) support future 505(b)(2) New Drug Application (NDA) submissionNew ...
PipelineReview.com1d
Accropeutics Announces First Patient Dosed in Phase Ib Study of RIPK2 Inhibitor AC-101
NEW YORK, NY, USA I 13, 2025 I Accropeutics Inc. (Accropeutics), a clinical-stage biotechnology company pioneering the development of novel ...
Hosted on MSN2d
Rallybio doses first subject in Phase II trial of treatment for FNAIT in Europe
US-based biotechnology company Rallybio has dosed the first subject in a Phase II trial evaluating RLYB212 as a potential ...
AnaptysBio announces Phase 2b RENOIR trial met primary endpoint
AnaptysBio (ANAB) announced statistically significant Week 12 data from the global 424-patient Phase 2b RENOIR trial of investigational ...
Hosted on MSN3d
Inhaled antibody therapy shows promise for COVID-19 treatment
By Tarun Sai Lomte A study finds that IN-006, a reformulated monoclonal antibody, is safe, well-tolerated, and delivers high ...
clinicaladvisor.com5d
FDA Approves Tocilizumab Biosimilar Avtozma
The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab-anoh), a biosimilar to Actemra ® (tocilizumab), in both intravenous (IV) and subcutaneous (SC) formulations.